2658-6533Research Results in Biomedicine2658-653310.18413/2658-6533-2023-9-4-0-43246Genetics<strong>Clinical and genetic characteristics of cystic fibrosis in the Republic of Bashkortostan</strong><strong>Clinical and genetic characteristics of cystic fibrosis in the Republic of Bashkortostan</strong>AyupovaGuzel R.AyupovaGuzel R.guzel8319@gmail.comKhusainovaRita I.KhusainovaRita I.ritakh@mail.ru20239400

Background: According to estimates of the World Health Organization, 40-50 thousand children worldwide are born each year with cystic fibrosis (CF), a monogenic disease with genetic heterogeneity and clinical variability due to regional and ethnic differences in the gene pool of populations. Monitoring of disease course and molecular pathogenesis in patients from different regions of multinational Russia is necessary to optimize algorithms of medical genetic counseling and improve the quality of life of patients. The aim of the study: Generalization and systematization of the results of dynamic clinical observations, laboratory and molecular genetic studies of patients with cystic fibrosis from the Republic of Bashkortostan (RB) to monitor the effectiveness of work with patients according to the registry of CF patients of the Republic of Bashkortostan, improvement of medical and genetic care for burdened families. Materials and methods: The study group included cystic fibrosis patients, their family members, and patients from the cystic fibrosis risk group living in the Republic of Bashkortostan &ndash; 400 people. Clinical-laboratory, molecular-genetic and statistical research methods, bioinformatic processing of NGS sequencing results were used. Results: During the period from 2019 to 2022 the number of patients in RB increased from 80 to 94, the incidence was 1.9 and 2.297 per 100 thousand population, respectively. The diagnosis was confirmed in the course of DNA diagnosis of 94 patients with cystic fibrosis in the Republic of Bashkortostan. Regional peculiarities of CF genetic architecture were determined: these are 12 pathogenic nucleotide sequence variants in CFTR gene: Phe508del, E92K, CFTRdele2,3, 3849+10kbC&gt;T, L138ins, G509D, 394delTT, N1303K, W1282X, Y84X, 2143delT, 1525-1G&gt;A are 94.9%, the frequency of the complex allele &ndash; c.1399C&gt;T (p.Leu467Phe, L467F) &ndash; 16.6%. Patients were prescribed targeted therapy. Conclusion: The study allowed us to identify regional peculiarities of clinical and genetic aspects of CF in order to apply a differential and personalized approach in the provision of medical care and planning of measures to improve the quality of life of CF patients in the region.

Background: According to estimates of the World Health Organization, 40-50 thousand children worldwide are born each year with cystic fibrosis (CF), a monogenic disease with genetic heterogeneity and clinical variability due to regional and ethnic differences in the gene pool of populations. Monitoring of disease course and molecular pathogenesis in patients from different regions of multinational Russia is necessary to optimize algorithms of medical genetic counseling and improve the quality of life of patients. The aim of the study: Generalization and systematization of the results of dynamic clinical observations, laboratory and molecular genetic studies of patients with cystic fibrosis from the Republic of Bashkortostan (RB) to monitor the effectiveness of work with patients according to the registry of CF patients of the Republic of Bashkortostan, improvement of medical and genetic care for burdened families. Materials and methods: The study group included cystic fibrosis patients, their family members, and patients from the cystic fibrosis risk group living in the Republic of Bashkortostan &ndash; 400 people. Clinical-laboratory, molecular-genetic and statistical research methods, bioinformatic processing of NGS sequencing results were used. Results: During the period from 2019 to 2022 the number of patients in RB increased from 80 to 94, the incidence was 1.9 and 2.297 per 100 thousand population, respectively. The diagnosis was confirmed in the course of DNA diagnosis of 94 patients with cystic fibrosis in the Republic of Bashkortostan. Regional peculiarities of CF genetic architecture were determined: these are 12 pathogenic nucleotide sequence variants in CFTR gene: Phe508del, E92K, CFTRdele2,3, 3849+10kbC&gt;T, L138ins, G509D, 394delTT, N1303K, W1282X, Y84X, 2143delT, 1525-1G&gt;A are 94.9%, the frequency of the complex allele &ndash; c.1399C&gt;T (p.Leu467Phe, L467F) &ndash; 16.6%. Patients were prescribed targeted therapy. Conclusion: The study allowed us to identify regional peculiarities of clinical and genetic aspects of CF in order to apply a differential and personalized approach in the provision of medical care and planning of measures to improve the quality of life of CF patients in the region.

cystic fibrosisgene CFTRregisterRepublic of Bashkortostancystic fibrosisgene CFTRregisterRepublic of BashkortostanСписок литературыZvereff VV, Faruki H, Edwards M, et al. Cystic fibrosis carrier screening in a North American population. Genetics in Medicine. 2014;16(7):539-546. DOI: https://doi.org/10.1038/gim.2013.188Krasovskiy SA, Adyan TA, Amelina EL, et al. Cystic fibrosis: some issues of epidemiology and genetics. Рractical pulmonology. 2019;9:45-50.Hamosh A, Scott AF, Amberger J, et al. Online Mendelian Inheritance in Man (OMIM). Human Mutation. 2000;15(1):57-61. DOI: https://doi.org/10.1002/(SICI)1098-1004(200001)15:1&lt;57::AID-HUMU12&gt;3.0.CO;2-GLoo TW, Clarke DM. Corrector VX-809 promotes interactions between cytoplasmic loop one and the first nucleotide-binding domain of CFTR. Biochemical Pharmacology. 2017;136:24-31. DOI: https://doi.org/10.1016/j.bcp.2017.03.020Callebaut I, Chong PA, Forman-Kay JD. CFTR structure. Journal of Cystic Fibrosis. 2018;17(2):S5-S8. DOI: https://doi.org/10.1016/j.jcf.2017.08.008Kashirskaya NU, Kapranov NI, Kondratieva EI, editors. Cystic fibrosis. 2nd edition, revised and enlarged. Moscow: ID &quot;MEDPRAKTIKA-M&quot;; 2021. Russian.Kelly J. Environmental scan of cystic fibrosis research worldwide. Journal of Cystic Fibrosis. 2017;16(3):367-370. DOI: https://doi.org/10.1016/j.jcf.2016.11.002Kondratieva EI, Kashirskaya NU, Kapranov NI, editors. National consensus (2nd edition) &quot;Cystic fibrosis: definition, diagnostic criteria, therapy&quot; 2018. M.: LLC &quot;Compania BORGES&quot;; 2018. Russian.Keogh RH, Szczesniak R, Taylor-Robinson D, et al. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. Journal of Cystic Fibrosis. 2018;17(2):218-227. DOI: https://doi.org/10.1016/j.jcf.2017.11.019Sherman VD, Kondratieva EI, Voronkova AY, et al. Influence of neonatal screening for cystic fibrosis by the example of patients of the Moscow region. Meditsinskiy sovet. 2017;18:124-128. Russian. DOI: https://doi.org/10.21518/2079-701X-2017-18-124-128Kondratieva EI, Krasovsky SA, Starinova MA, et al. editors. Register of patients with cystic fibrosis in the Russian Federation. Moscow: ID &quot;MEDPRAKTIKA-M&quot;; 2022. Russian.Cystic Fibrosis Worldwide [Internet] [cited 2019 June 12]. Available from: https://www.cfww.org/Lee TWR, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Journal of Cystic Fibrosis. 2003;2(1):29-34. DOI: https://doi.org/10.1016/S1569-1993(02)00141-8Zemanick ET, Sagel SD, Harris JK. The airway microbiome in cystic fibrosis and implication for treatment. Current Opinion in Pediatrics. 2011;23(3):319-324. DOI: https://doi.org/10.1097/mop.0b013e32834604f2Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis. 2018;17(2):153-178. DOI: https://doi.org/10.1016/j.jcf.2018.02.006Olivier M, Kavvalou A, Welsner M, et al. Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis. Frontiers in Pharmacology. 2023;14:1176815. DOI: https://doi.org/10.3389/fphar.2023.1176815Krasovskiy SA, Kashirskaya NYu, Chernyak AV, et al. Genetic characterization of cystic fibrosis patients in Russian Federation according to the National Register, 2014. Pulmonologiya. 2016;26(2):133-151. Russian. DOI: https://doi.org/10.18093/0869-0189-2016-26-2-133-151Nichols DP, Singh PK, Baines A, et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax. 2022;77(6):581-588. DOI: https://doi.org/ 10.1136/thoraxjnl-2021-217782All-Russian Association for Cystic Fibrosis Patients [Internet] [cited 2021 Dec 12]. Russian. Available from: https://mukoviscidoz.org/Kondratyeva EI, Amelina EL, ChernukhaMYu, et al. Review of clinical guidelines &laquo;Cystic fibrosis&raquo;, 2020. Pulmonologiya. 2021;31(2):135-146. (In Russ.). DOI: https://doi.org/10.18093/0869-0189-2021-31-2-135-146Chevalier B, Hinzpeter A. The influence of CFTR complex alleles on precision therapy of cystic fibrosis. Journal of Cystic Fibrosis. 2020;19(Suppl 1):S15-S18. DOI: https://doi.org/10.1016/j.jcf.2019.12.008Baatallah N, Bitam S, Martin N, et al. Cis variants identified in F508del complex alleles modulate CFTR channel rescue by small molecules. Human Mutation. 2018;39(4):506-514. DOI: https://doi.org/10.1002/humu.23389Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. New England Journal of Medicine. 2015;373(3):220-231. DOI: https://doi.org/10.1056/NEJMoa1409547Southern KW, Patel S, Sinha IP, et al. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews. 2018;8(8):CD010966. DOI: https://doi.org/10.1002/14651858.CD010966.pub2Kutsev SI, Izhevskaya VL, Kondratyeva EI. Targeted therapy for cystic fibrosis. Pulmonologiya. 2021;31(2):226-236. Russian. DOI: https://doi.org/10.18093/0869-0189-2021-31-2-226-236Amelina EL, Efremova AS, Melyanovskaya YuL, et al. Functional tests for assessment of residual CFTR channel activity and personalized selection of efficacious CFTR-modulators for cystic fibrosis patients with &lsquo;mild&rsquo; and &lsquo;severe&rsquo; genetic variants. Pulmonologiya. 2021;31(2):167-177. Russian. DOI: https://doi.org/10.18093/0869-0189-2021-31-2-167-177Efremova AS, Melyanovskaya YuL, Bulatenko NV, et al. Description of rare alleles of the CFTR gene in cystic fibrosis using functional tests and forskolin-induced swelling assay in rectal organoids. Pulmonologiya. 2021;31(2):178-188. Russian. DOI: https://doi.org/10.18093/0869-0189-2021-31-2-178-188&nbsp;